Lupeng Pharmaceutical
China - GuangzhouPharmaceutical
Focus: Lupeng Pharmaceutical is a China-based oncology and infectious disease-focused biotech founded in 2021, specializing in small molecule BTK inhibitors, Bcl-2/Bcl-xL inhibitors, and targeted protein degraders. The company is in early clinical development with a geographically concentrated presence in Guangzhou.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About Lupeng Pharmaceutical
AI assessmentNot HiringNo open roles listed right now. Follow Lupeng Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
LP-168 tablet
B-cell LymphomaClinical Trials (1)
NCT04993690A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
Phase 1Help build intelligence for Lupeng Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.